Slingshot members are tracking this event:

AstraZeneca's (AZN) Imfinzi Phase III PACIFIC trial for unresectable Stage III non-small cell lung cancer Interim Analysis Released

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details A planned interim analysis conducted by an Independent Data Monitoring Committee concluded that the trial has met its second of two primary endpoints by showing statistically-significant OS benefit with clinically-meaningful improvement in patients receiving Imfinzi compared to placebo. The safety and tolerability profile for Imfinzi was consistent with that reported at the time of the progression-free survival (PFS) analysis. AstraZeneca plans to present results from the PACIFIC trial at a forthcoming medical meeting.

Slingshot Insights Explained
Catalyst Date
Occurred on:
May 25, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Pacific Trial, Nsclc